| AD VANCES IN ALLERGEN IMMUNOTHE RAPY
Since its introduction, just over a century ago, researchers have endeavoured to provide a progressively deeper understanding of the chemical and physiological processes underpinning AIT. AIT is a highly effective treatment for immunoglobulin E (IgE-)-mediated diseases that has been shown to provide long-term relief of symptoms of allergic rhinitis and asthma; prevent the progression from allergic rhinitis to asthma in children; and have potential for preventing sensitization to house dust mite allergy in at-risk infants. [1] [2] [3] [4] [5] [6] [7] Looking into the future, we can expect this new understanding to present new opportunities to intervene to prevent allergic responses and to personalize treatment for patients. Biomarkers and improved diagnostic techniques will help to identify the likely best responders to a specific intervention, new therapeutic antigens and formulations that will help to optimize the patient's response.
| Opportunities for personalized medicine
Personalized medicine encompasses the interlinking concepts of precision medicine, stratified medicine and P4 medicine ( Figure 1 ).
The concept of personalized medicine is not new, but ongoing scientific and technological developments in bioinformatics, computational power and medical imaging offer the potential for clinicians to predict which patients will respond to which therapeutics. [8] [9] [10] While traditionally clinicians have focussed on selecting the right treatment for the patient (stratifying by phenotype), increasingly it will be more important to select the right patient for the treatment (stratifying by endotype or theratype) (see Box 1 for definitions). 8, 11, 12 Several inflammatory phenotypes have been identified using biomarkers, 11, 13, 14 but endotype classification remains elusive due to the complexity of these phenotypes; rather than a single endotype associated with a particular disease mechanism, asthma is believed to have a number of subendotypes associated with each mechanism.
However, such classification has obvious benefits for optimal treatment design.
9,10,13,15
| Biomarkers
Individual steps in the pathway from exposure to allergens to expression of the allergic response are characterized by the production of small molecules and proteins; typically, the most common of these (usually serum samples in allergic diseases) are used as biomarkers. 16 This field remains experimental in AIT; no biomarker predictive or indicative of clinical efficacy has so far been identified and validated. 16 This paucity of biomarkers to aid the identification of responders to AIT and for evaluating its efficacy objectively was recognized in a recent international consensus document, 17 which classified it as an unmet need.
The European Academy of Allergy and Clinical Immunology (EAACI) recognized this need 18 and established a task force to review all candidate biomarkers used in trials of AIT. 16 The aim of the task force was to:
• Collect and review surrogate and predictive immunological and clinical biomarkers, and biomarker data on the effect of AIT on allergenic rhinitis with and without asthma.
• Identify surrogate candidate biomarkers that may reflect, or correlate with, the immunological and clinical effects of immunotherapy.
• Identify surrogate predictive clinical and immunological candidate biomarkers to monitor the effects of AIT in the target organ and systemically during the early and late allergic responses following immunotherapy.
• Identify surrogate cellular, humoral and molecular candidate biomarkers to monitor the effects of AIT during and after discontinuation of treatment.
• Confirm (or reject) the candidate biomarkers for monitoring AIT.
The resulting report from the extensive literature research and subsequent discussions by the members of the task force consists of recommendations for seven biomarker domains (Table 1) . 16 Having reviewed advantages and disadvantages and identified challenges and unmet needs in each domain, the task force recommended that future biomarker studies should have a novel design approach that aims to identify clinical relevance as surrogate or predictive markers of the efficacy of AIT. In particular, it recommended investigating allergen-specific (s)IgG4 as a biomarker for compliance and sIgE: total (t)IgE ratio and IgE-FAB as markers of clinical outcome. 16 The design of clinical trials of AIT, in particular the choice of endpoints, should be carefully considered to obtain good quality data on potential biomarkers and to validate biomarkers.
A total of 3 recent studies have led to the identification of a set of biomarkers that may prove useful for monitoring treatment efficacy. None of the potential biomarkers has yet been validated, and larger studies are required to achieve this.
A pilot study suggests that measuring levels of sIgE, sIgG4 and functional antibodies in nasal fluid, rather than in peripheral blood, can detect differences in IgE and IgG4, and in a range of components of IgG4, in treated and untreated patients with allergies. Moreover, data from nasal fluid correlate more closely with symptom scores (M. H. Shamji, unpublished data, personal communication). In addition to validation of these findings, more research is required to investigate the role of other immunoglobulins, especially IgA, in target organ samples from patients undergoing AIT.
Stimulation with allergens is known to activate basophils, which can be assessed by measuring surface activation markers, such as CD63, CD203c and CD107a, or by measuring histamine release. Histamine release is most easily measured in assays based on binding histamine to intracellular DAO. An early method achieved this using an enzyme-affinity-gold method, 19 but a recent study evaluated a simpler and more immediately available method based on detecting fluorochrome-labelled DAO using flow cytometry in patients with allergic rhinitis. 20 Following in vitro grass pollen allergen stimulation, the proportion of fluorochrome-labelled DAO-negative basophils was significantly higher in those who received SCIT and SLIT compared with non-treated atopic controls (all. P < .001). Similarly, F I G U R E 1 Personalized medicine in practice BOX 1 Useful definitions in personalized medicine 10, 11 
Definitions
• Phenotype: any observable characteristic of a disease without any implication of a mechanism.
• Endotype: a subtype of a disease condition, which is defined by a distinct pathophysiological mechanism.
Endotypes should link the key pathogenic mechanisms with clinical phenotype via biomarkers.
• Theratype: variant classified according to response to a therapeutic.
A patient with the same phenotype and endotype as another patient, but who does not respond to the same treatment, has a different theratype.
• Biomarker: measurable indicator used to examine any aspects of health or disease. C1QA and FcgRIIIa were upregulated in active responders and downregulated in the active non-responders. There was also a correlation between these five biomarkers and efficacy, which was seen as early as 2 months, after initiation of AIT. 21 It should be noted that, often, the choice of objectives and endpoints in the design of AIT studies results in the generation of heterogeneous data, which are not helpful for the identification of potential biomarkers. A better understanding of how such noise is generated, and how it can be eliminated, will help elevate the discovery and validation of biomarkers with clinical relevance in AIT. In the last 2 years, several studies and reviews have sought to link allergic disease phenotypes and endotypes with potential targets for treatment in a precision medicine approach. 13, 14, [22] [23] [24] [25] [26] In January 2017, the PRACTALL group published a summary on the potential for precision medicine in allergic disease, which concluded that while some progress has been made in defining endotypes for allergic disease and identifying biomarkers to guide a precision medicine approach to treatment, further validation and quantification of these biomarkers are needed to allow their translation into practice in the clinical management of allergic disease. 18 The process of using endotypes and biomarkers to manage patients with allergies may seem abstract to some clinicians; however, it has been shown that factors such as obesity, diet, micro- recently been shown that levels of histamine-secreting gut bacteria are increased in patients with asthma. 31 Non-obese patients with asthma produce more histamine-secreting bacteria than obese patients with asthma, providing a physical marker for stratifying patients at risk for severe asthma. 31 Similarly, the composition of the diet-relative proportions of protein, fat and carbohydrate-is known to affect the composition of the gut microbiome. 32 A more recent study has shown that the composition of the microbiome (available from samples of faeces) can be used to predict obesity and severe asthma (M. Jutel, personal communication). The investigators used these findings to hypothesize that regional differences in diet could account for differences in predisposition to disease and even responses to AIT. This type of testing is relatively inexpensive and accessible; so if its utility can be validated, there is great promise here for patient stratification. 35 This group of candidates is narrowed down using a series of computational and experimental (mainly based on mass spectroscopy) methods. The resulting candidates are then tested extensively by in vitro assays and selected animal models: to progress and qualify for development, the candidates must elicit a specific and correct polarized immune response, be representative of the natural source, conserved and have a good safety profile. 35 Another recent technique, systems vaccinology (Table 2) ing the numbers of vaccinations that patients require. [40] [41] [42] The development of new adjuvants will be discussed in the next section.
| Precision medicine

|
| Adjuvants and delivery systems
Adjuvants act as enhancers or potentiators of AIT, mostly by activating CD40, CD80 and CD86-although there are many other proteins that could be targeted. (PEG) hydrogels that incorporate adjuvants with the drug. 47, 48 There are some issues that need to be taken into account when attempting to transfer this technology to AIT. Vaccination-driven antibody responses include TLR-5 dependent responses (interestingly, TLR5-mediated sensing of gut microbiota plays an essential role in the efficacy of vaccines). 49 Similarly, these nanoparticles have been shown to enhance IL10, IgG1 and CD8 responses, and increase Th2 immunity, whereas allergists would be looking for enhanced IgG4 and reduced Th2 immunity. Although liposomes and hydrogel formulation of drugs for inflammatory skin disease have been approved for use, to date, uses in AIT have only been investigated in mice. 46, 48, 50 This means there are no safety data for this nanoparticle plus allergen combination. From a safety perspective, it will be necessary to choose the right adjuvant (or nanoparticle) for the right allergen; for example, allergens with anaphylactic potential will initially be the secondary choice.
To really capitalize on the potential of these new adjuvant approaches, a rational approach is required to design a system that will deliver the required IgG4 enhancement and reduced Th2 immunity. Systems biology approaches will play a key role in streamlining this process and will help to hone the list of possible adjuvants down to those that will be of most use to allergists. 56 The study did achieve its pri- Circassia's CAT-SPIRE (synthetic peptide immuno-regulatory epitopes) for cat allergy has been evaluated in a long-term, Phase 3, double-blind placebo-controlled field study (CATALYST). 59 The study followed a successful Phase 2, AEC-based study. 60 Patients A consistent problem with moving new AIT products through to registration is the difficulty in replicating the results of Phase 2 studies in Phase 3. A number of differences in study design and patient selection for Phase 2 and Phase 3 studies might contribute to this problem (Table 3) , but so far none of these hypotheses have been tested.
| Summary
New developments in technology offer many opportunities to improve diagnosis and treatment for patients with allergies. It is important to define how these technologies-and especially their products-can best be used to deliver clinically meaningful improvements in therapy for patients.
| HOT TOPICS IN THE RE GULATION OF ALLERGEN IMMUNOTH ERAPY
| Meeting the needs of polysensitized patients
The enactment of European Directive 2001/83 EC has changedand will continue to change-the environment for allergy treatment by defining products for AIT as medicines, which therefore means that they require individual marketing authorizations (MAs), which are granted on the basis of successful clinical studies with single agents for individual allergies. Notwithstanding this, the Directive does allow for allergens (singly and in mixtures) to continue to be prescribed on a named patient basis-that is, without the need for a MA-at the prescriber's discretion. This is an important concession for patients with rare or infrequent allergies, and for patients who have, or appear to have, more than one allergy. 62 In 2016, a survey was conducted among >1000 physicians prescribing AIT in 15 countries (not including the USA) to assess how physicians used AIT and the effect of changing regulations on their practice. This is the largest survey of its type ever conducted. The survey found that:
63,64
• The majority of physicians supported adherence to guidelines that aimed to standardize AIT and wanted high-quality, documented allergen products.
• The majority of patients presenting for AIT were polysensitized/ polyallergic, but the majority of prescriptions were for single allergies. Respondents preferred to use only single, characterized allergens; they were less enthusiastic for mixtures.
• Most polyallergic patients are treated one allergy at a time, receive more than one single allergen, or in a minority of cases receive a named patient product (NPP) consisting of a mixture of allergens.
The survey concluded that most physicians believed that the majority of their polysensitized patients' needs could be met without allergen mixtures, either using sequential single allergen immunotherapies or parallel single immunotherapies, but that, on average, 14% of all patients might still require tailored allergen mixtures. 63, 64 The British Society for Allergy and Clinical Immunology guidelines note that "single allergen immunotherapy may be effective against the relevant allergen (source) in polysensitized patients and that a single allergen used for immunotherapy as part of a multi-allergen mixture may retain efficacy against the relevant allergen". 65 Despite this recommendation and the fact that many of the physicians questioned in the survey 63, 64 take this approach, there are some questions that should be addressed concerning the use of multiple sequential or parallel injections/ingestions of single allergens. In particular, are there any safety issues to be considered? A particular concern might be the overall dose of aluminium that patients were receiving in multiple injections of allergens. Should there be a limit to the number of single agents a patient should receive in this way?
The British guidelines do not recommend the use of mixtures of allergens to treat multiple allergies due to lack of evidence. 65 there remains a lack of internationally recognized and standardized harmonization on the definition of pollen seasons based on pollen count data. Therefore, an EAACI task force initiative has been initiated and has published an EAACI Position Paper with consensusbased definitions on "pollen season," "high-pollen season" (or "peakpollen period") and "high-pollen days" for different pollen species, 71 ( Table 4 ).
In addition, a high variation in pollen count data has been found between different regions and across the different years analysed; therefore, a large degree of patient's individual pollen exposure during the pollen season can be assumed. 67, 72 In addition, a high (yearly) variation of allergenicity of pollen grains has been demonstrated in preliminary analyses. 73 These factors may confound the proof of The problem is not restricted to pollen, and regional differences in the prevalence of (and hence exposure to) other aero allergens such as mite species 77 also impact the outcomes of trials.
Allergen exposure chambers may bypass some of these methodological restrictions (Box 2). 67 An increasing number of facilities (including mobile chambers) of various sizes exist across the world and have been used in multiple Phase 2 trials (Table 5) .
In its guideline, the EMA proposes specific requirements for pivotal Phase 3 studies in AIT in which the primary objective includes measurement of combined symptom and medication scores as, for example, standardized by the EAACI, 78 under natural allergen exposure. 66 Moreover, it is clearly stated that in Phase 3 trials in AIT challenge tests (such as allergen challenges in AEC facilities) or para- The definition for this pollen is only valid for Mediterranean areas where Cupressus species dominate the Cupressaceae concentrations.
symptoms". 66 However, it is acknowledged that an AEC can be seen Advantages of allergen exposure chambers
• Exposure to a defined, controlled allergenic environment (particles/m 3 , temperature, air-pressure and humidity).
• Absence of confounding allergens (especially in polysensitized patients).
• No bias of rescue-medication intake.
• No impact of patient's individual activities (outdoor vs indoor activities) or poor compliance.
• Good supervision of patients.
• More efficient collection of biological samples from participants.
• Dose ranging and onset of action can be analysed.
• Requires fewer subjects (positive impact on costs, ethical benefit).
PFAAR ET AL. One important task will be the proof of inter-chamber comparability regarding results on AIT efficacy. Another important task is to investigate the correlation of AIT treatment effect sizes as demonstrated in AEC with those as found in a field trial under natural exposure in a "hybrid" study design. The EMA has stated that it expects AIT to act in the same way in both adults and children, but it is possible that the magnitude of the effect and the safety profile could differ. 66, 85 Thus, the EMA emphasized that dose-finding efforts for safety and efficacy performed in adults do not have to be duplicated with children or adolescents. It also believes that children with allergic rhinoconjunctivitis may ultimately derive greater benefit from AIT than adults because it can prevent progression to asthma. 7, 86, 87 For these reasons and due to specific demands of the EMA Pediatric Committee (PDCO), the agency needs to see evidence from at least one longterm (3-year double-blind, placebo-controlled and 2-year blinded follow-up) study to demonstrate long-term effects (i.e in allergic rhinoconjunctivitis) or prevention of allergy (and development of asthma). 66, 85 The types of studies which are recommended are randomized, placebo-controlled double-blind parallel group trials to evaluate efficacy, safety and tolerability. Children aged from 5 to <12 years should be assessed separately from those aged 12 to <18 years.
Two interconnected problems arise from these requirements.
Five years is a long time in the life of a child, and half of the children participating in a study are randomized to the placebo arm. Physicians who have been involved in paediatric studies have found it difficult to recruit and retain patients once this is explained to parents.
There are also ethical issues associated with continuing to give children placebo (particularly with the possibility that they could develop asthma in the long term) when it is clear that treatment is effective, as was the case in recent studies. 7, 86, 87 The difficulties in including patients will be possibly compounded by the numbers of children required to be recruited into trialsalthough the EMA has not provided guidance on this. To meet the requirements of recent and current MA applications, more than 1000 children will need to be screened for each individual study. 7 The feasibility of randomized controlled trials in the context of the Paediatric Investigator Plan 85 to provide evidence on which to base treatment decisions has been questioned. 88, 89 It has been proposed that observational studies and clinical registers could provide additional evidence. This is highly pertinent to AIT in children and should prompt further discussions between physicians, manufacturers and regulators about how data requirements can be met. The EMA allows the extrapolation of dose-finding data from adult trials to children. 85 For an indication in children the Paul-Ehrlich-Institut (PEI) (Langen, Germany) accepts short-term studies in children. These studies may start as soon as efficacy and safety in a short-term Phase 3 study in adults has been shown. These studies can be performed in parallel with studies or deferrals according to an approved PIP. If efficacy and safety is shown in children in the first year, the PEI can grant the indication "treatment of allergic symptoms" also for children, provided there is still compliance with the PIP (S. Vieths, personal communication).
The current environment for PIPs in AIT is very unsatisfactory, with a number of important questions-not least concerning the ethics of current requirements-necessary to be resolved.
It must be in the interests of all stakeholders-especially children and their parents-for ongoing discussions to arrive at concrete solutions.
| Summary
In this era of evidence-based medicine, a clear demand of both regulatory bodies and physicians requires that products for AIT have to thoroughly meet modern methodological standards for proving clinical efficacy and safety. However, AIT differs from pharmacotherapy.
The introduction of Directives designed to bring AIT into line with the requirements for small molecule drugs has been met with a number of difficulties. Ongoing discussions between all stakeholders about the minimal requested level of evidence needed that is necessary to ensure that patients-especially children-continue to have access to AIT are essential. will also need to provide reports of process variations, results of stability testing, periodic safety update reports (PSURs) and data on safety and efficacy during routine use. 94, 95 As diagnostic allergens are the cornerstone of allergology, this is a matter of great concern to manufacturers, clinicians and patients.
| TH E FUTUR E OF DIAGNOSTIC ALLERGEN S FOR IN VIVO TESTING
The situation presents a deep dilemma for allergists. Of course, they want the reassurance that the extracts they are using for testing are of good quality, safe and effective; however, simple economics dictates that rare allergens and forms of test other than the widely used skin prick tests are less likely to be supported by manufacturers because the cost of registration (see Table 6 ) will exceed the value of sales (or, alternatively, the price increase needed to cover the costs will make the test non-viable for payers). 94, 96 It is expected that many currently used tests will not be available in the future. In France, Germany and the Netherlands, already there have been sharp reductions in the numbers of available diagnostic tests ( Figure 4 ). In the Netherlands, clinicians now only have six authorized prick test diagnostic allergens (grasses, grass mixture, tree mixture, cat, Alternaria, mites and histamine). They cannot officially test in vivo for reactions to any other allergens.
As all diagnostic tests are manufactured involving an industrial process, there is no option for them to be the subject of NPPs. In some cases, it will be possible to replace these in vivo diagnostics Paediatric investigation plan (PIP; 50 patients) 100 000
Quality development (to demonstrate compliance with GMP) 80 000
Total cost of submission package 300 000
Additional costs Further definition is required on the nature of the data presented to regulatory authorities. There is no absolute definition of sensitivity and specificity for these tests, and this is made more complicated by the fact that there is no guidance on whether the test should diagnose sensitization to the allergen or clinically relevant sensitization (ie, allergic disease). Usually, diagnostic tests only reveal sensitization to the allergen, and doctors must use their skill and experience to discriminate between sensitization and allergic disease.
The European Academy of Allergy and Clinical Immunology also has successfully drawn allergen manufacturers into the conversation.
It has proposed that manufacturers consider "exchanging" some allergens-particularly rare allergens-in some markets, so that all manufacturers are not faced with supporting all allergens in all markets. Another conversation that needs to take place concerns acceptance by health authorities, insurers and patients that costs for these tests will rise.
| Summary
There is general agreement that skin tests and provocation tests are the cornerstones of the diagnosis of allergic diseases, and some would go as far as to say that without them the allergy community risks losing its credibility-even its very existence. The issue is to The project group has published systematic reviews of the current available evidence, and two papers highlighting the role of regulatory authorities and of primary care clinicians caring for allergy patients, respectively. [102] [103] [104] [105] [106] [107] [108] [109] [110] The guidelines will highlight the benefits of AIT at the public and policymakers level, too, illustrating potential savings in direct and indirect costs of treating allergic disease. Dissemination and implementation of the guidelines is essential to achieving EAACI's ultimate ambition of implementing excellence in the care of allergic diseases. 101 These guidelines have the potential to reduce variations in clinical practice and, most importantly, form a basis for continuous collaborations between centres of excellence and primary and secondary care. Such vertical and horizontal networks will be instrumental not only in identifying gaps and barriers that can be overcome by more education, networking and research, but also in driving changes in policies and legislation affecting patients and allergy specialists at the EU and national level. Allergies are a public health issue, thus there is a need for national programmes in addition to AIT guidelines, such as the Finnish Allergy Programme 2008-2018. 111 Involving all the above mentioned stakeholders in the implementation of a national programme, we can replace the avoidance strategy with a tolerance induction strategy where AIT is the key tool.
| CONCLUSIONS
The 2017 FASIT Workshop provided a platform for fruitful and interesting discussion and debate between all groups of global stakeholders in the field of AIT. It covered a broad range of topics covering basic research, field testing and regulatory issues and addressed some specific, current challenges that will dictate how AIT continues to respond to patients' needs in the future. This workshop also highlighted the forthcoming EAACI guidelines for best practice in AIT.
These guidelines will set new standards for awareness of the principles of the only disease-modifying treatment option for patients with allergic diseases as well as clinical practice. This review presents an insight into those discussions and highlights unmet needs and possible solutions to them for the future. 
